{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.74","upperLimit":"10.68","value":"8.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"}],"units":"Participants"}],"description":"OS is defined as the time from the first dose of study drug treatment until the date of death due to any cause.\n\nOS is presented overall for all participants who received ADCT-402, as specified in protocol section 7.4.","dispersionType":"95% Confidence Interval","groups":[{"description":"In Part 1 (dose escalation) participants received intravenous (IV) infusions of ADCT-402, at escalating doses according to a 3+3 study design. Doses assessed:\n\n* Dose Level 1: 15 μg/kg on Day 1 of each 3 week cycle (Q3W)\n* Dose Level 2: 30 μg/kg Day 1 Q3W\n* Dose Level 3: 60 μg/kg Day 1 Q3W\n* Dose Level 4: 90 μg/kg Day 1 Q3W\n* Dose Level 5: 120 μg/kg Day 1 Q3W\n* Dose Level 6: 150 μg/kg Day 1 Q3W\n* Dose Level 7: 200 μg/kg Day 1 Q3W and on Day 1 of each 6 week cycle (Q6W).\n\nIn Part 2 (expansion), participants received intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Parts 1 and 2: ADCT-402"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one dose of study treatment with a valid baseline disease assessment and at least one valid post-baseline disease assessment. Results are pooled for all arms as specified in the protocol.","reportingStatus":"POSTED","timeFrame":"Baseline to End of Study (a maximum of 18 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}